Scynexis Inc (SCYX)

Jun 15, 2025

Millennium Management LLC Takes Position in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World

Jun 15, 2025

Jun 11, 2025

Squarepoint Ops LLC Takes Position in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World

Jun 11, 2025

Jun 10, 2025

Jane Street Group LLC Buys New Holdings in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World

Jun 10, 2025

Jun 06, 2025

Bright Minds Biosciences (NASDAQ:DRUG) & SCYNEXIS (NASDAQ:SCYX) Head-To-Head Survey - Defense World

Jun 06, 2025

Jun 03, 2025

Northern Trust Corp Has $186,000 Stake in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World

Jun 03, 2025

May 29, 2025

Scynexis resumes dosing in Phase III MARIO study after lengthy delay - MSN

May 29, 2025

May 29, 2025

SCYNEXIS resumes Phase 3 antifungal study after FDA lift By Investing.com - Investing.com South Africa

May 29, 2025

May 29, 2025

SCYNEXIS, Inc. (SCYX) Resumes Phase III Dosing for Brexafemme After 19-Month FDA Hold - Insider Monkey

May 29, 2025

May 28, 2025

Scynexis resumes patient dosing in Phase 3 MARIO study - TipRanks

May 28, 2025

May 28, 2025

SCYNEXIS Resumes Patient Dosing In Phase 3 MARIO Study - marketscreener.com

May 28, 2025

May 28, 2025

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study | SCYX St - GuruFocus

May 28, 2025

May 28, 2025

GSK Involved in SCYNEXIS's Phase 3 Study Milestone Dispute | GSK Stock News - GuruFocus

May 28, 2025

May 28, 2025

SCYNEXIS resumes Phase 3 antifungal study after FDA lift - Investing.com Australia

May 28, 2025

May 28, 2025

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study | SCYX Stock News - GuruFocus

May 28, 2025

May 28, 2025

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study - The Manila Times

May 28, 2025

May 28, 2025

SCYNEXIS Restarts Critical Phase 3 Trial for Life-Threatening Infection, Faces $30M GSK Payment Battle - Stock Titan

May 28, 2025

May 19, 2025

SCYNEXIS Faces Challenges Amidst Antifungal Developments - TipRanks

May 19, 2025

May 19, 2025

Biosergen taps antifungal expert as board member - Biostock

May 19, 2025

May 16, 2025

FDA lifts hold on Scynexis trial; Incyte’s Zynyz notches another FDA approval - Endpoints News

May 16, 2025

May 16, 2025

SCYNEXIS (NASDAQ:SCYX) Now Covered by Analysts at StockNews.com - Defense World

May 16, 2025

May 16, 2025

SCYNEXIS Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 16, 2025

May 16, 2025

Scynexis: Q1 Earnings Snapshot - CT Insider

May 16, 2025

May 15, 2025

SCYX Reports Strong Q1 Revenue, Progress in Clinical Trials | SCYX Stock News - GuruFocus

May 15, 2025

May 15, 2025

SCYX: Cash Reserves and Debt Repayment Update | SCYX Stock News - GuruFocus

May 15, 2025

May 15, 2025

SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update | SCYX Stock News - GuruFocus

May 15, 2025

May 15, 2025

SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times

May 15, 2025

May 15, 2025

SCYNEXIS INC SEC 10-Q Report - TradingView

May 15, 2025

May 14, 2025

Sector Update: Health Care Stocks Fall Late Afternoon - marketscreener.com

May 14, 2025

May 12, 2025

News - Biostock

May 12, 2025

May 12, 2025

SCYNEXIS (SCYX) Projected to Post Earnings on Wednesday - Defense World

May 12, 2025

May 08, 2025

JPMorgan Chase & Co. Makes New Investment in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World

May 08, 2025

May 02, 2025

SCYNEXIS, Inc. (NASDAQ:SCYX) Shares Sold by LPL Financial LLC - Defense World

May 02, 2025

May 01, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

May 01, 2025

May 01, 2025

StockNews.com Begins Coverage on SCYNEXIS (NASDAQ:SCYX) - Defense World

May 01, 2025

Apr 30, 2025

GSK 'well positioned' for potential tariffs after beating forecasts - marketscreener.com

Apr 30, 2025

Apr 28, 2025

Aspergillosis Market Expected to Rise by 2034, Regeneron, Pulmocide, Astellas Pharma, Cipla, Pulmatrix, F2G, Cellix Bio, SCYNEXIS, TFF, Matinas BioPharma, Amplyx Pharmaceuticals, Cidara Therapeutics, - Barchart.com

Apr 28, 2025

Apr 23, 2025

SCYNEXIS (NASDAQ:SCYX) Upgraded by StockNews.com to Hold Rating - Defense World

Apr 23, 2025

Apr 22, 2025

Blastomycosis Treatment Market Overall Study Report 2025-2032 | Janssen, Scynexis Inc, Novartis AG, Marck & Co. - openPR.com

Apr 22, 2025

Apr 22, 2025

Second-Generation Antifungal Aims to Address Invasive Fungal Disease - ContagionLive

Apr 22, 2025

Apr 10, 2025

Acute Vulvovaginal Candidiasis Treatment Market Poised - openPR.com

Apr 10, 2025

Apr 08, 2025

SCY-247 shows promise against resistant fungal infections By Investing.com - Investing.com South Africa

Apr 08, 2025

Apr 08, 2025

SCY-247 shows promise against resistant fungal infections - Investing.com

Apr 08, 2025

Apr 08, 2025

Breakthrough: SCYNEXIS's New Antifungal Drug Defeats 171 Resistant Fungal Strains in Latest Tests - Stock Titan

Apr 08, 2025

Apr 03, 2025

Aspergillosis Market on Track for Major Expansion by 2034, According to DelveInsight | F2G, Pulmatrix, TFF Pharmaceuticals, Scynexis, Pulmocide - The Globe and Mail

Apr 03, 2025

Mar 22, 2025

SCYNEXIS (NASDAQ:SCYX) Lowered to Sell Rating by StockNews.com - Defense World

Mar 22, 2025

Mar 20, 2025

SCYNEXIS (SCYX) to Release Earnings on Thursday - Defense World

Mar 20, 2025

Mar 17, 2025

Research Analysts Issue Forecasts for SCYNEXIS FY2029 Earnings - Defense World

Mar 17, 2025

Mar 15, 2025

StockNews.com Downgrades SCYNEXIS (NASDAQ:SCYX) to Sell - Defense World

Mar 15, 2025

Mar 14, 2025

SCYNEXIS Full Year 2024 Earnings: Misses Expectations - Yahoo Finance

Mar 14, 2025

Mar 14, 2025

SCYNEXIS Reports 2024 Financial Results and Updates - TipRanks

Mar 14, 2025